Ethics Approval The procedures involving the care and use of animals in this study were reviewed and approved by CR-MWN Institutional Animal Care and Use Committee before conduct (Testing Facility Study Number 886-526). During the study, the care and use of animals were conducted with guidance from the guidelines of the USA National Research Council.

2 years ago

PK/PD data • Preclinical • IO biomarker

CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • EGF (Epidermal growth factor) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3) • TMEFF2 (Transmembrane Protein With EGF Like And Two Follistatin Like Domains 2)

JNJ-8902

over2years

JNJ-70218902 (JNJ-902), a TMEFF2 x CD3 bispecific antibody, in prostate cancer: Initial results from a phase I dose escalation study (ESMO 2022)

Part 1 (dose escalation) is ongoing and Part 2 (dose expansion) of study will initiate once part 2 expansion dose is declared. Selection of part 2 expansion dosage is currently being adjusted and dose information will be presented.

over 2 years ago

P1 data

TMEFF2 (Transmembrane Protein With EGF Like And Two Follistatin Like Domains 2)

AR expression

JNJ-8902

over2years

Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models (AACR 2022)

Targeting TMEFF2 with the TMEFF2 × CD3 bispecific antibody JNJ-902 elicited robust T cell-mediated responses in both prostate cancer cells and xenograft models. Based on these data, a phase 1 dose escalation trial of JNJ-902 in patients with mCRPC is currently ongoing (NCT04397276).

over 2 years ago

Preclinical • Late-breaking abstract

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • IL10 (Interleukin 10) • CASP3 (Caspase 3) • EGF (Epidermal growth factor) • GZMB (Granzyme B) • TMEFF2 (Transmembrane Protein With EGF Like And Two Follistatin Like Domains 2)

CD8 expression • IL2RA expression

JNJ-8902